Position in NVS
as of Jun 30, 2026
· filed Aug 17, 2026
Position Value
$39,180
+$993 QoQ
Shares Held
250
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.08%
of 13F equity value
Holder Rank
#1,450
of 1,602 holders
Holding Since
Mar 2023
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Nalls Sherbakoff Group, LLC holds $591,233 across 10 Drug Manufacturers - General names. NVS ranks #7 (6.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MRK |
Merck & Co., Inc.
|
1,511 | $194,163 | |
| 2 | JNJ |
Johnson & Johnson
|
403 | $102,349 | |
| 3 | BMY |
Bristol Myers Squibb Co
|
1,341 | $77,268 | |
| 4 | ABBV |
AbbVie Inc.
|
272 | $68,446 | |
| 5 | LLY |
ELI LILLY & Co
|
42 | $50,376 | |
| 6 | PFE |
Pfizer Inc
|
1,678 | $40,406 | |
| 7 | NVS |
Novartis AG
This page
|
250 | $39,180 | |
| 8 | SNY |
Sanofi
|
300 | $12,798 |
All Filings in NVS
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $39,180 | 250 | Shares | Sole | 2026-08-17 | |
| 2026-03-31 | $38,187 | 250 | Shares | Sole | 2026-08-17 | |
| 2025-12-31 | $34,467 | 250 | Shares | Sole | 2026-03-12 | |
| 2025-09-30 | $32,060 | 250 | Shares | Sole | 2026-03-12 | |
| 2025-06-30 | $30,252 | 250 | Shares | Sole | 2026-03-12 | |
| 2025-03-31 | $27,870 | 250 | Shares | Sole | 2026-03-12 | |
| 2023-12-31 | $25,242 | 250 | Shares | Sole | 2024-04-09 | |
| 2023-09-30 | $25,465 | 250 | Shares | Sole | 2023-10-17 | |
| 2023-06-30 | $25,227 | 250 | Shares | Sole | 2023-10-17 | |
| 2023-03-31 | $23,000 | 250 | Shares | Sole | 2023-10-17 | |
| No filing history on record for this holder in this stock. | ||||||